New products, merger to drive Glaxo - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

New products, merger to drive Glaxo

Aug 2, 2000

Glaxo seems to be a new high these days. The proposed merger with SmithKline is likely to come through sooner than expected. The company has reported very healthy results for the second quarter with a topline growth of over 27%, when the overall pharmaceutical industry is growing by not more than 10% per annum. Most important, Glaxo’s parent seems willing to introduce new products through the listed company. What however seems to be driving the company’s stock seems to be the sooner–than–expected merger with SmithKline.

The merged company with a market share of 7% will be way ahead of competitors Cipla and Ranbaxy. It will have brands such as Iodex, Augmentin (an amoxycillin–clavulanic acid combination), Engerix (Hepatitis B vaccine), Zevit and Livogen (vitamins and minerals), which will complement its prescription led product profile. Glaxo, at present, has a presence in a large number of therapy areas (over 60% of the market). It is a market leader in 80% of the segments in which the company operates and has a large portfolio of over 200 product packs. Besides, the company enjoys the trust of the medical profession. Its prescription brands such as Betnovate (dermatologicals), Zinetac (ranitidine), Becadexamin (vitamin) Cetzine (anti–histamine) are as well known as over the counter products in their own right. The company has a clean balance sheet and a first class management. Besides, the merged entity will also command an enviable marketing network that will go a long way in its attempt to increase market share.

SmithKline Consumer has a presence in health food drinks through the brands ‘Horlicks’, ‘Viva’ and ‘Maltova’. Glaxo, on the other hand, has sold its brand ‘Farex’ which operated in a similar space a few year’s back. Since the parent’s operations are likely to be restricted to pharmaceuticals it is quite possible that the merged company in India could disinvest the healthfood operations. Another side effect of the impending merger is that Glaxo is likely to inherit SmithKline’s 100% subsidiary in India i.e. SmithKline Beecham Asia. Whether ‘Crocin’ ‘Tums’ and ‘Eno’ continue to remain a part of the parent’s 100% subsidiary will demonstrate the parent’s attitude towards the minority shareholders.

As far as new products are concerned the company has lined up a slew of new launches over the next 12–18 months. Overall the company would continue to focus on the therapy areas of the future such as respiratory, anti–virals, osteoporosis and consolidate in dermatologicals, gastrointestinals and antibiotics.

Glaxo's new products
Brand Purpose Introduced
Hepitec Hepatitis–B Yes
Seretide Asthma Yes
Lamictal Epilepsy No
Valtrex Viral Infections No
Epivir AIDS Yes
Combivir AIDS Yes
Zoderm Oxiconazole No
Histofreezer Wart removal Yes

Glaxo has posted a mixed performance over the last two year’s. However, the pending mergers with Burroughs Wellcome and SmithKline Beecham and its recent attempts to restructure its operations have the potential to rev up its performance in the coming year’s.


Equitymaster requests your view! Post a comment on "New products, merger to drive Glaxo". Click here!

  

More Views on News

GSK PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 2.2% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, GSK PHARMA has posted a net profit of Rs 1 bn (down 2.2% YoY). Sales on the other hand came in at Rs 6 bn (down 17.7% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

More Views on News

Most Popular

My Top Stock to Buy in this Market Selloff (Profit Hunter)

Sep 22, 2020

The recent correction offers a great opportunity to buy this high conviction smallcap stock.

Can the Nifty Fall to 10,200? (Fast Profits Daily)

Sep 24, 2020

The Nifty has reached an important support level today. If it breaks then we could see further downside.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...

I Believe These Stocks Will Deliver the Most Outsized Returns in 2021 and Beyond (Profit Hunter)

Sep 23, 2020

Rules of the racetrack can help you bag the biggest gainers of the coming decade.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Sep 30, 2020 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - ACTAVIS COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS